Nasdaq · Healthcare

Eton Pharmaceuticals, Inc. (ETON)

As-reported financials and recent SEC filings for Eton Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$80.0M

Net income

$-4.6M

Net margin

-5.8%

Diluted EPS

—

ROE

-17.6%

P/E (TTM)

—

Market cap

—

Debt / equity

0.8×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$80.0M	$39.0M	$31.6M	$21.3M	$21.8M
Gross profit	$42.7M	$23.4M	$21.1M	$14.3M	$19.0M
Operating income	$-844,000	$-2.6M	$-1.2M	$-8.3M	$-1.5M
Net income	$-4.6M	$-3.8M	$-936,000	$-9.0M	$-2.0M
Diluted EPS	—	—	—	—	—

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-30

1442026-06-26

1442026-06-25

1442026-06-23

1442026-06-17

42026-06-17

8-K2026-06-09

1442026-06-02

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ETON

Search Eton Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.